Skip to main content
QURE
NASDAQ Life Sciences

FDA收紧加速审批流程令罕见病生物技术公司陷入"混乱",uniQure暴跌33%

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
8
Price
$10.12
Mkt Cap
$646.84M
52W Low
$7.76
52W High
$71.5
Market data snapshot near publication time

summarizeSummary

华尔街日报的"街头耳语"栏目强调FDA加速审批途径的收紧，尤其影响罕见病药物开发。该机构最近的行动，包括一系列备受关注的拒绝，表明批准门槛大大提高。这一分析跟随uniQure最近宣布其亨廷顿治疗被拒绝加速审批，导致该公司周一股价暴跌33%。该文章指出2024年至2025年加速审批的数量大幅下降，从20个下降到9个。Moderna被提及为过去的监管不确定性最终解除的例子。这种转变为生物技术公司，尤其是那些依赖加速途径和较小数据集的罕见病治疗开发商，带来了巨大的不确定性和增加的风险，根本性地改变了投资格局和许多公司在该行业的估值模型。投资者应该密切关注未来FDA的指导和决定，以及公司如何调整其临床开发战略以应对这种更加严格的监管环境。

在该公告发布时，QURE的交易价格为$10.12，交易所为NASDAQ，所属行业为Life Sciences，市值约为$6.5亿。 52周交易区间为$7.76至$71.50。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed QURE - Latest Insights

QURE
Apr 27, 2026, 7:00 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on Significant Share Issuance Authority and Capital Increase Amidst Clinical Setbacks
Sentiment: Negative
View Wiseek Article
QURE
Apr 16, 2026, 5:00 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Shareholders to Vote on Significant Share Issuance Authority and Capital Increase Amidst Clinical Setbacks
Sentiment: Negative
View Wiseek Article
QURE
Mar 23, 2026, 9:40 PM EDT
Source: Access Newswire
Importance Score:
8
Securities Fraud Lawsuit Filed Against uniQure N.V. Over 49% Stock Drop Following FDA Approval Delay
Sentiment: Negative
View Wiseek Article
QURE
Mar 03, 2026, 5:30 AM EST
Source: Dow Jones Newswires
Importance Score:
8
FDA's Stricter Accelerated Approval Process Creates 'Chaos' for Rare Disease Biotech, uniQure Plunges 33%
Sentiment: Negative
View Wiseek Article
QURE
Mar 02, 2026, 7:24 AM EST
Filing Type: 10-K
Importance Score:
9
FDA Rejects Lead Gene Therapy BLA Pathway, Recommends New Trial; Other Programs Face Setbacks
Sentiment: Negative
View Wiseek Article
QURE
Mar 02, 2026, 7:09 AM EST
Source: Dow Jones Newswires
Importance Score:
8
UniQure Reports $3.46 Per Share Loss for 2025
Sentiment: Negative
View Wiseek Article
QURE
Mar 02, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
9
FDA Rejects AMT-130 Phase I/II Data for Marketing Application, Recommends Phase III Study
Sentiment: Negative
View Wiseek Article
QURE
Feb 26, 2026, 9:20 PM EST
Source: Acceswire
Importance Score:
7
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Sentiment: Negative
View Wiseek Article
QURE
Jan 13, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
uniQure Reports Positive 36-Month Phase I/II Data for AMT-130 in Huntington's Disease
Sentiment: Positive
View Wiseek Article
QURE
Jan 09, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
8
uniQure Schedules Key FDA Type A Meeting for AMT-130 Accelerated Approval Pathway
Sentiment: Neutral
View Wiseek Article